HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
Cheng‐Yuan Peng(China Medical University), Jia‐Horng Kao(National Taiwan University Hospital), Kuo‐Chih Tseng(Buddhist Tzu Chi General Hospital), Chia‐Chi Wang(Taipei Tzu Chi Hospital), Tai‐Chung Tseng(National Taiwan University Hospital), Hans Hsienhong Lin(Tzu Chi University), Tsai-Yuan Hsieh(Tri-Service General Hospital), Tung‐Hung Su(National Taiwan University), Chih‐Lin Lin(National Tsing Hua University), Tsung‐Cheng Hsieh(Tri-Service General Hospital)
Cited by 14
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
|Annals of Internal Medicine|2016|364